These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32708048)

  • 21. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation.
    Lee TJ; Lee JT; Park JW; Kwon TK
    Biochem Biophys Res Commun; 2006 Dec; 351(4):1024-30. PubMed ID: 17097066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
    Kim EH; Kim HS; Kim SU; Noh EJ; Lee JS; Choi KS
    Oncogene; 2005 Oct; 24(46):6877-89. PubMed ID: 16007142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.
    Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T
    Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aplysin sensitizes cancer cells to TRAIL by suppressing P38 MAPK/survivin pathway.
    Liu J; Ma L; Wu N; Liu G; Zheng L; Lin X
    Mar Drugs; 2014 Sep; 12(9):5072-88. PubMed ID: 25257790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marine actinomycete crude extracts with potent TRAIL-resistance overcoming activity against breast cancer cells.
    Elmallah MIY; Micheau O; Eid MAG; Hebishy AMS; Abdelfattah MS
    Oncol Rep; 2017 Jun; 37(6):3635-3642. PubMed ID: 28440502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells.
    Griffin D; Wittmann S; Guo F; Nimmanapalli R; Bali P; Wang HG; Bhalla K
    Gynecol Oncol; 2003 Apr; 89(1):37-47. PubMed ID: 12694652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells.
    Tang SY; Zhong MZ; Yuan GJ; Hou SP; Yin LL; Jiang H; Yu ZΥ
    Oncol Rep; 2013 Feb; 29(2):474-80. PubMed ID: 23135489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
    Engesæter BO; Sathermugathevan M; Hellenes T; Engebråten O; Holm R; Flørenes VA; Mælandsmo GM
    Cancer Biol Ther; 2011 Jul; 12(1):47-58. PubMed ID: 21508672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sea Cucumber (
    Kim JL; Park SH; Jeong S; Kim BR; Na YJ; Jo MJ; Jeong YA; Yun HK; Kim DY; Kim BG; You S; Oh SC; Lee DH
    Nutrients; 2019 May; 11(5):. PubMed ID: 31083595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
    Kim EH; Kim SU; Choi KS
    Oncogene; 2005 Jan; 24(5):838-49. PubMed ID: 15531913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis.
    Hörnle M; Peters N; Thayaparasingham B; Vörsmann H; Kashkar H; Kulms D
    Oncogene; 2011 Feb; 30(5):575-87. PubMed ID: 20856198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity.
    Raviv Z; Zilberberg A; Cohen S; Reischer-Pelech D; Horrix C; Berger MR; Rosin-Arbesfeld R; Flescher E
    Br J Pharmacol; 2011 Nov; 164(5):1433-44. PubMed ID: 21486277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP.
    Mühlethaler-Mottet A; Bourloud KB; Auderset K; Joseph JM; Gross N
    Oncogene; 2004 Jul; 23(32):5415-25. PubMed ID: 15094781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.